Drug Trial Radar · NCT05472662
A Study to Compare the Effects of Two Propellants in Adults With Mild Asthma
Last checked: Nov 19, 2026Latest source record: Oct 15, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
25
Actual
Start
Aug 3, 2022
Primary completion
Oct 31, 2022
Study completion Oct 31, 2022
Sponsor
- Lead sponsor
- Chiesi Farmaceutici S.p.A.Industry
- Sponsor type
- Industry
- First posted
- Jul 25, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase IIa, multicentre, single dose, randomised, double blind, controlled, 2 way cross-over study to evaluate the potential for bronchoconstriction of the new HFA-152a propellant (single dose) versus the marketed HFA-134a propellant (single dose) in adults with mild asthma. HFA=Hydrofluoroalkane
Conditions
- Asthma
Interventions
Placebo 152aDrug
Placebo pressurised metered-dose inhaler (pMDI) formulated with the 152a propellant
Placebo 134aDrug
Placebo pressurised metered-dose inhaler (pMDI) formulated with the 134a propellant
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety: Relative Change From Baseline* in Forced Expiratory Volume in 1 s (FEV1) -- 15 Min Post-doseTime frame: At 15 min post-dose after T1.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Medicine Evaluation Unit Limited
Manchester, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.